Robert Michael Dudley - Feb 1, 2022 Form 4 Insider Report for Transcode Therapeutics, Inc. (RNAZ)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Thomas A. Fitzgerald, as Attorney-in-Fact
Stock symbol: RNAZ
Transactions as of: Feb 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/3/2022, 05:03 AM
Previous filing: Jul 8, 2021
Next filing: Jun 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNAZ	Stock Option (Right to Buy)	Award	$0	+135K		$0.00	135K	Feb 1, 2022	Common Stock	135K	$2.45	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.

Content

Thirty-three percent (33%) of the Stock Options shall vest and become exercisable on the one year anniversary of Vesting Commencement Date (February 1, 2022). Thereafter, the remaining sixty-six percent (66%) of the Stock Options shall vest and become exercisable in 24 equal monthly installments on the last day of each such month following the first anniversary of the Vesting Commencement Date, provided the Reporting Person continues to have a Service Relationship with the Company on each vesting date.